(Q37489533)

20 August 2017

1 reference

title

New therapeutic approaches to hepatitis C virus (English)

1 reference

20 August 2017

1 reference

1 reference

1

Naoya Sakamoto

1 reference

20 August 2017

Mamoru Watanabe

2

1 reference

20 August 2017

21 May 2009

1 reference

Journal of Gastroenterology

20 August 2017

1 reference

20 August 2017

44

1 reference

20 August 2017

643-649

1 reference

20 August 2017

7

1 reference

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

20 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00535-009-0084-0

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-009-0084-0

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-009-0084-0

Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-009-0084-0

The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells

21 January 2018

1 reference

12 December 2020

Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide

1 reference

12 December 2020

Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.

1 reference

12 December 2020

Synthetic agonists of Toll-like receptors 7, 8 and 9.

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin

1 reference

12 December 2020

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

1 reference

12 December 2020

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

1 reference

12 December 2020

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

1 reference

12 December 2020

Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial

1 reference

12 December 2020

Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases

1 reference

12 December 2020

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

1 reference

12 December 2020

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.

1 reference

12 December 2020

Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C

1 reference

12 December 2020

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

12 December 2020

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

1 reference

12 December 2020

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

1 reference

12 December 2020

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

12 December 2020

Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons

1 reference

12 December 2020

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

12 December 2020

Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells

1 reference

12 December 2020

Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine

1 reference

12 December 2020

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

1 reference

12 December 2020

Host sphingolipid biosynthesis as a target for hepatitis C virus therapy

1 reference

12 December 2020

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

1 reference

12 December 2020

Robust hepatitis C virus infection in vitro

1 reference

12 December 2020

Glucosidase inhibitors as antiviral agents for hepatitis B and C.

1 reference

12 December 2020

Specific inhibition of hepatitis C virus replication by cyclosporin A.

1 reference

12 December 2020

Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions

1 reference

12 December 2020

Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs

1 reference

12 December 2020

Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine.

1 reference

12 December 2020

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

1 reference

12 December 2020

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

12 December 2020

Functional association of cyclophilin A with HIV-1 virions

1 reference

12 December 2020

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

1 reference

12 December 2020

Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Molecular virology of hepatitis C virus

1 reference

12 December 2020

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

12 December 2020

Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor

1 reference

12 December 2020

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

1 reference

12 December 2020

Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid

1 reference

12 December 2020

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

1 reference

12 December 2020

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

1 reference

12 December 2020

Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha

1 reference

12 December 2020

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

1 reference

12 December 2020

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

12 December 2020

Epidemiology of hepatitis C

1 reference

12 December 2020

Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment

1 reference

12 December 2020

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

1 reference

12 December 2020

The treatment of chronic viral hepatitis

1 reference

12 December 2020

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

12 December 2020

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

1 reference

12 December 2020

Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans

1 reference

12 December 2020

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

12 December 2020

Nitazoxanide as a broad-spectrum antiparasitic agent

1 reference

12 December 2020

Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication

1 reference

12 December 2020

Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins

1 reference

12 December 2020

Gateways to clinical trials

1 reference

12 December 2020

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

12 December 2020

The hepatitis C virus life cycle as a target for new antiviral therapies

1 reference

12 December 2020

10.1007/S00535-009-0084-0

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19455277